Bibliography
- LINCOFF AM, BITTL JA, HARRINGTON RA et al: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA (2003) 289:853–863.
- DOGGRELL SA: Clinical trials with glycoprotein IIb/IIIa antagonists - no benefit without bleeding. Drugs of Today (2001) 37:509–531.
- BITTL JA, STRONY J, BRINKER JA et al.: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N. Engl.' Med. (1995) 333:764–769.
- LINCOFF AM, KLEIMAN NA, KOTTKE-MARCHANT K et al.: Bivalirudin with planed or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for ischemic Events Trial (CACHET). Am. Heart J. (2002) 143:847–853.
- LINCOFF AM, BITTL JA, KLEINMAN NS et al.: The REPLACE 1 trial: a pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade. J. Am. Coll. Cardiol (2002) 39:16A.
- SCHWEIGER MJ, CHANGEZI HU, NAGLIERI-PRESCOD D, COOK JR: Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention. Clin. Thec (2003) 25:225–234.
- NEUMANN FJ, HOCHHOLZER W, POGATSA-MURRAY G, SCHOMIG A, GAWAZ M: Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J. Am. Coll. Cardiol (2001) 37:1323–1328.
- BATCHELOR WB, TOLLESON TR, HUANG Y et al: Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Circulation (2002) 106:1470–1476.
- TOPOL EJ, MOLITERNO MD, HERRMANN MD et al.: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl. J. Med. (2001) 344:1888–1894.
- TOPOL EJ, MARK DB, LINCOFF AM et al.: Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Lancet (1999) 354: 2019-2024.
- ANDERSON KM, CALIFF RM, STONE GW et al.: Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J. Am. Coll. Cardiol (2001) 37:2059–2065.
- ANTMAN EM, BRAUNWALD E: A second look at bivalirudin. Am. Heart J. (2001) 142:929–931.